Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. (Q39068190)
Jump to navigation
Jump to search
scientific article published on 20 December 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. |
scientific article published on 20 December 2016 |
Statements
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study (English)
Michael W Konstan
Edward F McKone
Richard B Moss
Gautham Marigowda
Simon Tian
David Waltz
Xiaohong Huang
Barry Lubarsky
Jaime Rubin
Stefanie J Millar
David J Pasta
Nicole Mayer-Hamblett
Wayne Morgan
Gregory S Sawicki